pivotal Phase III

Related by string. Pivotal Phase III * Pivotal . pivotals . PIVOTAL . Pivotals : pivotal undecided superdelegates . pivotal Phase . Pivotal filly . Pivotal CRM . Phase III pivotal / phase . phases . Phases . PHASE : Phase III clinical trials . Phase III trials . Phase III clinical . Phase 2b clinical / iii . Iii . IIIs . IIID : Star Wars Episode III . Guitar Hero III . Tha Carter III . Mission Impossible III * *

Related by context. All words. (Click for frequent words.) 86 Phase III clinical 83 pivotal Phase 82 Phase 2b clinical 81 Phase III 81 Phase IIb 80 Phase IIb clinical 77 Phase 2a clinical 77 Phase III pivotal 77 Phase 2b study 77 Phase III clinical trials 77 Phase 2b trial 76 Phase IIb trial 76 Phase IIa clinical 76 Phase 2b 76 phase IIb 75 Phase 1b 75 Phase Ib 75 Phase 2a 75 phase IIa clinical 74 Phase IIa trial 74 phase IIb clinical 74 Phase 1b clinical 73 phase IIa 73 Phase IIa 73 randomized Phase 73 Phase III trials 73 Phase II 72 confirmatory Phase 3 72 confirmatory Phase III 72 Phase Ib clinical 72 Phase 1b trial 72 dose escalation trial 71 Phase 2a trial 71 registrational 70 placebo controlled Phase 70 phase 2a 69 Phase IIIb clinical 69 clinical trial 68 SUCCEED trial 68 Phase 1a 68 Phase IIb trials 68 oral ridaforolimus 68 Phase IIIb 68 Phase Ib study 68 dose escalation study 68 Phase Ia 67 placebo controlled Phase III 67 registrational trial 67 randomized Phase IIb 67 multicenter Phase 67 Phase #b/#a 67 Phase Ib II 67 dose escalation Phase 67 multiple ascending dose 66 dose escalation clinical 66 investigational drug 66 phase Ib 66 initiate Phase 66 APEX PD 66 phase IIb trial 66 Phase IIa trials 66 Phase 1a clinical 66 JAK inhibitor 65 randomized Phase III 65 Phase III randomized 65 Phase 65 COMFORT II 65 randomized controlled Phase 65 relapsed refractory multiple myeloma 65 Phase IIB 65 Amrubicin 65 Investigational Device Exemption IDE 65 mipomersen 64 Phase 2b kidney transplant 64 randomized placebo controlled 64 multicenter Phase II 64 Phase Ib IIa 64 Corlux 64 phase Ib clinical 64 Phase III randomized controlled 64 Phase Ib clinical trials 64 phase IIb study 64 single ascending dose 64 placebo controlled 64 blind randomized placebo 64 placebo controlled clinical 64 investigational compound 64 BRIM3 64 BRIM2 64 Zerenex 64 BCX# 64 Phase III Pivotal 64 ADVANCE PD 64 Phase 2b clinical trials 64 Pivotal Phase III 64 PEG PAL 64 Phase #/#a 64 pivotal bioequivalence 64 multicenter Phase III 64 glufosfamide 64 metastatic hormone refractory 64 Phase #b/#a clinical 64 Dacogen injection 64 GALNS 64 clinical trials 63 Pivotal Phase 63 oral deforolimus 63 multicenter clinical 63 NO# [002] 63 viral kinetic 63 FOLOTYN ® 63 NDA submission 63 MAA submission 63 double blind placebo 63 randomized double 63 teduglutide 63 multicenter randomized placebo controlled 63 LibiGel Phase III 63 Phase IIb clinical trials 63 dirucotide 63 Omigard 63 Zenvia Phase III 63 placebo controlled randomized 63 initiate Phase IIb 63 masked placebo controlled 63 opioid induced bowel dysfunction 63 forodesine 63 rNAPc2 63 diabetic neuropathic pain 63 rALLy clinical trial 62 PRX # 62 dose escalation 62 ruxolitinib 62 Augment Injectable 62 tanespimycin 62 randomized multicenter 62 ongoing Phase 1b 62 multicenter randomized Phase 62 Phase III HEAT 62 Phase IIb kidney transplant 62 CoFactor 62 IIa trial 62 dose cohorts 62 Phase 1b dose escalation 62 alvimopan 62 randomized controlled 62 Phase III confirmatory 62 Phenoptin 62 ofatumumab 62 cetrorelix 62 BLA submission 62 alvespimycin 62 TG MV 62 PLK1 SNALP 62 EDEMA3 62 PDX pralatrexate 62 PROPEL trial 62 double blinded placebo 62 ANCHOR trial 62 Phase III Clinical Trial 62 pharmacokinetic PK study 62 Cloretazine R VNP#M 62 Amigal 62 RDEA# 62 Zenvia ™ 62 dextromethorphan quinidine 62 docetaxel Taxotere R 62 ThermoDox ® 62 PS# [001] 62 PREOS 62 EOquin 62 perifosine 62 Marqibo 62 Marketing Authorization Application MAA 61 phase IIb III 61 prospective multicenter 61 INCB# [002] 61 INCB# [001] 61 multicenter phase 61 ILLUMINATE 61 New Drug Application 61 QNEXA 61 elotuzumab 61 GetGoal Phase III 61 ELACYT 61 HspE7 61 blind placebo controlled 61 Biologics License Application BLA 61 Diabetic Macular Edema 61 ofatumumab HuMax CD# 61 IMGN# 61 phase IIIb 61 relapsed multiple myeloma 61 NEBIDO 61 bicifadine 61 randomized Phase 2b 61 Phase III placebo controlled 61 ozarelix 61 multicenter randomized double 61 metastatic castrate resistant 61 OvaRex ® MAb 61 axitinib 61 investigational pan BCR 61 IND enabling 61 ILUVIEN ® 61 lomitapide 61 ZYBRESTAT 61 PANVAC VF 61 selective androgen receptor modulator 61 TMC# C# 61 randomized controlled multicenter 61 phase III ACCLAIM 61 relapsing remitting multiple sclerosis 61 VEGF Trap 61 Special Protocol Assessment 61 Proxinium TM 61 trastuzumab DM1 T DM1 61 ENDEAVOR IV 61 GEM OS1 61 MEND CABG 61 Ophena TM 61 Phase IIb III 61 subcutaneous formulation 61 PREOS R 61 blinded randomized placebo controlled 61 APPRAISE 61 MOZOBIL 61 dose cohort 60 EFAPROXYN 60 blinatumomab 60 TELCYTA 60 Pivotal Trial 60 Aryplase 60 NP2 Enkephalin 60 label multicenter 60 CLIRS trial 60 PRE SURGE 60 celgosivir 60 severe hypercholesterolemia 60 Urocidin 60 Fodosine 60 metastatic CRPC 60 tesmilifene 60 Medidur TM FA 60 clinical pharmacology studies 60 Initiate Phase 60 LUMINATE 60 PFO migraine 60 Androxal TM 60 Cloretazine ® 60 SYMMETRY trial 60 label dose escalation 60 double blinded randomized 60 fidaxomicin Phase 3 60 AP# [003] 60 Aurexis 60 lorcaserin Phase 60 FOLOTYN 60 acyclovir Lauriad R 60 tamibarotene 60 blind randomized 60 MEND CABG II 60 Phase #b/#a trial 60 sNDA submission 60 assessing T DM1 60 lorvotuzumab mertansine 60 HuMax EGFr 60 Alzhemed TM 60 histone deacetylase HDAC inhibitor 60 Diabetic Macular Edema DME 60 OLpur TM H2H 60 CEQ# 60 MAGE A3 ASCI 60 Phase III Clinical Trials 60 IND submission 60 hormone refractory prostate cancer 60 CB2 selective receptor agonist 60 RG# [001] 60 GATTEX 60 GATTEX ® 60 ZYBRESTAT fosbretabulin 60 Asentar 60 Fibrillex TM 60 AQ4N 60 Pirfenidone 60 MERLIN TIMI 60 KRN# 60 relapsing multiple sclerosis 60 Phase IIa clinical trials 60 AIR CF1 60 Initiated Phase 60 Iluvien ® 60 Tanespimycin 60 omacetaxine mepesuccinate 60 XIENCE V Stent System 60 IIa clinical trial 60 sunitinib malate 60 generation PNP inhibitor 60 LUX Lung 60 lintuzumab 60 Anturol 60 Phase IIb Trial 60 Fx #A 60 BLOOM DM 60 elagolix 60 RSD# oral 60 EOquin TM 60 trastuzumab emtansine T DM1 59 MBP# [001] 59 BLA filing 59 pharmacokinetic PK 59 obatoclax 59 Vicinium TM 59 tivozanib 59 LibiGel ® 59 Ceplene 59 metastatic sarcomas 59 reslizumab 59 Phase 2b randomized 59 IMA# 59 AEG# 59 Azedra 59 Multiple Ascending Dose 59 Alpharadin 59 T DM1 59 Troxatyl 59 microplasmin 59 LEVADEX 59 multicentre randomized 59 refractory metastatic colorectal cancer 59 Allovectin 7 59 LEVADEX ™ 59 carfilzomib 59 tesetaxel 59 Randomized Phase 59 Pivotal Study 59 multicenter randomized controlled 59 peginesatide 59 octreotide implant 59 Phase III psoriasis 59 velaglucerase alfa 59 MIST II 59 Bronchitol 59 controlled multicenter 59 Icatibant 59 AeroLEF TM 59 AVADO 59 leading oral taxane 59 hypoxia activated prodrug 59 Plicera 59 pralatrexate 59 IIa clinical 59 interferon gamma 1b 59 APF# 59 ThermoDox R 59 sapacitabine 59 IMPACT IMmunotherapy 59 deforolimus 59 Iluvien 59 RE SURGE 59 clofarabine 59 Phase 2b monotherapy 59 TMC# [002] 59 valopicitabine 59 Phase #/#a trial 59 Soliris TM eculizumab 59 TASKi2 59 Marketing Authorization Application 59 Ereska 59 Annamycin 59 initiate Phase Ib 59 rALLy trial 59 Archexin 59 TBC# 59 evaluating REVLIMID 59 PHX# 59 Zelrix 59 albinterferon alfa 2b 59 Phase 1b clinical trials 59 Glybera R 59 bazedoxifene 59 Amoxicillin PULSYS 59 huC# DM4 59 GLP toxicology studies 59 Phase IIIb study 59 Elagolix 59 CHAMPION PCI 59 dosing cohorts 59 SNT MC# 59 CORLUX 59 confirmatory Phase 59 pharmacokinetic 59 virus HCV protease inhibitor 59 AzaSite Plus 59 European Sepsis Trial 59 Biologics License Application 59 aflibercept 59 ALN TTR# 59 dalbavancin 59 BAY #-# 59 fostamatinib 59 NUVIGIL 59 ToGA 59 investigational oral 59 neratinib 59 Cellegesic 59 voreloxin 59 PREVAIL 59 Serada 59 AZX# 59 ularitide 58 arzoxifene 58 T Pred 58 cell lymphoma CTCL 58 OncoVEX GM CSF 58 brivaracetam 58 Tesetaxel 58 Bicifadine 58 Phase III multicenter 58 picoplatin 58 Zingo TM 58 ACAPODENE 58 confirmatory clinical 58 pharmacokinetics PK 58 investigational 58 diarrhea predominant irritable 58 unblind 58 AEGR 58 Cimzia TM 58 Randomized Phase II 58 CRx 58 Phase IIB clinical 58 Ixempra 58 refractory CLL 58 Augment Bone Graft 58 TELINTRA 58 treatment naive genotype 58 randomized clinical 58 CRMD# 58 ponatinib 58 naproxcinod 58 EDEMA4 58 dependent kinase inhibitor 58 PDE4 inhibitor 58 OPT CHF 58 antibody MAb 58 avanafil 58 initiate Phase 1b 58 L BLP# 58 Anturol TM 58 ITAX 58 evaluating tivozanib 58 MINDSET 58 Besivance 58 cutaneous T cell 58 eltrombopag 58 PROMACTA 58 Myocet 58 Ophena 58 NVA# 58 aclidinium bromide 58 initiate Phase 2b 58 investigational antiplatelet agent 58 acyclovir Lauriad ® 58 mertansine 58 Virulizin R 58 New Drug IND 58 prospective randomized 58 oral calcitonin 58 label multicenter Phase 58 subcutaneously administered 58 CLARITY study 58 LibiGel 58 Prostate AdenoCarcinoma Treatment 58 Anturol ® 58 methylnaltrexone 58 HGS ETR1 58 lintuzumab SGN 58 interferon beta 1b 58 AIR CF2 58 Plenaxis TM 58 preclinical 58 Phase lll 58 blinded placebo controlled 58 Canvaxin 58 XL# [003] 58 Veronate 58 GOUT 58 HuMax CD4 58 PSN# [002] 58 SPIRIT III 58 LymphoStat B TM 58 AZX# Phase 58 HCV SPRINT 58 elacytarabine 58 lymphoma CTCL 58 satraplatin 58 HGS# 58 Onrigin 58 Jevtana 58 ganetespib 58 Combination REOLYSIN R 58 Shigamabs ® 58 custirsen 58 multicenter 58 torezolid phosphate 58 Aclidinium 58 AMR# 58 RELOVAIR ™ 58 belinostat 58 ENDEAVOR III 58 eculizumab 58 miconazole Lauriad R 58 oral formulation 58 LymphoStat B 58 cannabinor 58 Luveniq 58 ZACTIMA 58 HER2 positive metastatic breast 58 Initiate Phase II 58 Dyloject 58 talactoferrin 58 SinuNase TM 58 DR Cysteamine 58 SPIRIT FIRST 58 pseudobulbar affect PBA 58 II Clinical Trial 58 linaclotide 58 NGX# 58 multicentre 58 randomized controlled clinical 58 Ozarelix 58 Microplasmin 58 PROVENGE ® 58 multicenter placebo controlled 58 Civacir 58 metastatic castration resistant 58 pharmacokinetic studies 58 SinuNase 58 myelofibrosis 58 Tarceva TM 58 budesonide foam 58 ACTEMRA TM 58 multicenter multinational 58 AVASTIN 58 MAP# 58 sorafenib tablets 58 darusentan 58 denufosol 57 Efficacy Results 57 tolerability 57 bortezomib Velcade R 57 prospective randomized controlled 57 ecallantide 57 TLK# 57 blind multicenter 57 lexidronam injection 57 metastatic HRPC 57 Mipomersen 57 symptomatic BPH 57 Dyloject TM 57 XL# XL# XL# 57 pertuzumab 57 oral prodrug 57 multicentre randomized double 57 balsalazide tablet 57 PRIMO CABG 57 Nexavar ® 57 ascending dose 57 Phase 2a clinical trials 57 TAXUS Element Stent System 57 PRECISE trial 57 initiated Phase Ib 57 R#/MEM # 57 PROVENGE sipuleucel T 57 ENRICH trial 57 ALSYMPCA 57 REVLIMID lenalidomide 57 Application BLA 57 velafermin 57 Adlea 57 Proellex TM 57 dose dose escalation 57 TRISENOX 57 COSIRA trial 57 midstage trials 57 Quinamed 57 DASISION 57 teriflunomide 57 AeroLEF 57 REOLYSIN ® 57 sodium Injection 57 Ceflatonin R 57 refractory multiple myeloma 57 Clolar ® 57 anticancer compound 57 mGluR5 negative 57 Panzem R NCD 57 Gabapentin GR 57 Marketing Authorisation Application 57 Personalized Immunotherapy 57 dacetuzumab SGN 57 FavId 57 dyskinesia PD LID 57 prospective observational 57 Fibrin Pad 57 BST CarGel R 57 Phase III Trial 57 ORENCIA ® 57 generation purine nucleoside 57 lumiliximab 57 unique alkylating agent 57 luliconazole 57 Omigard TM 57 PSMA ADC 57 Androxal 57 treatment naïve genotype 57 PRT# 57 ospemifene 57 ALN VSP Phase 57 Ambrisentan 57 Rhucin 57 UPLYSO 57 Laquinimod 57 apaziquone 57 pegloticase 57 topical formulation 57 Onalta ™ 57 ascending doses 57 Xibrom QD 57 BCIRG 57 Genasense 57 CR# vcMMAE 57 zalutumumab 57 immunotherapeutic agent 57 SCH # 57 dosing cohort 57 eniluracil 57 Genasense ® oblimersen 57 fidaxomicin 57 BR.# 57 INDs 57 Prosaptide 57 active comparator 57 vilazodone 57 Matrix Phase 2b 57 thymalfasin 57 ceftaroline 57 EchoCRT 57 omacetaxine 57 Viramidine 57 NPSP# 57 fidaxomicin Phase 57 PRECiSE 57 pradefovir 57 Amitiza 57 ATryn R 57 sNDA 57 bardoxolone 57 comparing alemtuzumab 57 Exherin TM 57 palifosfamide 57 PHASE III 57 LibiGel testosterone gel 57 HCD# [002] 57 Genasense ® 57 refractory gout 57 ARDIS 57 Aflibercept 57 thorough QT 57 FIRAZYR 57 Phase 2b Clinical Trial 57 HRPC 57 Acapodene 57 pralatrexate injection 57 Zenvia TM 57 Serdaxin ® 57 Locteron ® 57 INSPIRE Trial Phase III 57 Ketotransdel 57 monotherapy 57 prospective multicenter randomized 57 Alocrest 57 Restanza 57 dirucotide MBP# 57 Topical Interferon Alpha 2b 57 rilonacept 57 Ostarine 57 Glybera 57 evaluating T DM1 57 methylnaltrexone bromide 57 vosaroxin 57 BiTE R 57 IV APAP 57 regadenoson 57 multicenter prospective 57 investigational humanized monoclonal antibody 57 PEGINTRON TM 57 Phase III ADT 57 ocrelizumab 57 BEMA TM Fentanyl 57 Firazyr 57 APEX AMI trial 57 TRANSFORMS 57 rindopepimut 57 Northera 57 Panzem R 57 Xcytrin R 57 Vicriviroc 57 PEG Interferon lambda 57 Sorafenib HCC Assessment 57 Phase IIb Clinical Trial 57 compound INCB# 57 Biologic License Application BLA 57 IL# PE#QQR 57 Acetavance 57 enzastaurin 57 evaluating Vectibix 57 Dacogen 57 KNS # 57 Traficet EN 57 MONOVISC 57 Dapagliflozin 57 Teysuno 57 vidofludimus 56 FTY# fingolimod 56 liprotamase 56 PRTX 56 HCV protease inhibitor 56 Evoltra 56 Rhucin R 56 Completes Patient Enrollment 56 desvenlafaxine succinate 56 Nasdaq PGNX today 56 Board DSMB 56 OHR/AVR# 56 Chemophase 56 miconazole Lauriad ® 56 Drug Eluting Stent System 56 toremifene 56 Darusentan 56 AZILECT R 56 crofelemer 56 oral mucositis 56 Taxotere ® 56 JANUVIA 56 Daclizumab 56 THALOMID 56 Arzerra TM 56 humanized monoclonal antibody 56 indolent NHL 56 StemEx R 56 Perifosine 56 EcoNail 56 abiraterone acetate 56 HoFH 56 SUPPRELIN R LA 56 VNP#M 56 MGCD# [001] 56 LEP ETU 56 Ofatumumab 56 Clonicel 56 pharmacodynamics 56 Initiates Phase II 56 Capesaris 56 Cloretazine 56 ATL# [001] 56 Bezielle 56 Azixa 56 zanolimumab 56 relapsing remitting MS RRMS 56 DDP# 56 ISIS # 56 randomized multicenter Phase III 56 ABSORB clinical 56 IIb clinical trial 56 RE LY ® 56 Phase III TRIST 56 Sapacitabine 56 Ventavis 56 Phase III Psoriasis 56 PRECISE 56 orBec 56 Junovan 56 KRYSTEXXA TM pegloticase 56 StaphVAX 56 huN# DM1 56 seliciclib CYC# 56 fosbretabulin 56 novel histone deacetylase 56 PIX# trial 56 neurogenic orthostatic hypotension 56 phase III isavuconazole 56 Vectibix panitumumab 56 Shigamabs R 56 perifosine KRX 56 Safinamide 56 AIMM trial 56 evaluating nimotuzumab 56 CTA# Injection 56 SEPET TM 56 Memryte 56 superficial bladder cancer 56 AEZS 56 QNEXA ® 56 oxymorphone ER 56 enoximone capsules 56 Ocrelizumab 56 SILENOR TM 56 REVIVE Diabetes 56 Locteron 56 Rhucin ® 56 OAB overactive bladder 56 Inc. Nasdaq VVUS 56 budesonide MMX 56 NASDAQ CXSP announced 56 Zybrestat 56 platinum refractory 56 Onco TCS 56 RHUCIN 56 RSD# 56 prospective randomized placebo 56 midstage studies 56 HCV RESPOND 2 56 unresectable malignant mesothelioma UMM 56 Æterna Zentaris 56 intravenous formulation 56 aclidinium 56 candidate AQ4N 56 MNTX 56 ataluren 56 ABSORB trial 56 Marketing Authorisation Application MAA 56 pain palliation 56 StemEx 56 oxypurinol 56 Amoxicillin PULSYS Phase III 56 Vilazodone 56 Fentanyl TAIFUN R 56 RoACTEMRA 56 alogliptin 56 BEMA Buprenorphine 56 IDX# 56 CIP ISOTRETINOIN 56 maribavir 56 PrevOnco ™ 56 OLYMPIA registry 56 GATTEX TM 56 QLT# 56 Clolar 56 EVIZON 56 Bepreve 56 TOCOSOL Paclitaxel 56 RSD# iv 56 RIBBON 56 sBLA 56 CONSERV 56 PI3K/Akt pathway inhibitor 56 Phase III VISTA 56 NKTR 56 AZILECT ® 56 alemtuzumab Campath 56 lesinurad 56 Parkinson disease levodopa induced 56 Sym# 56 cystinosis patients 56 EVEREST II 56 blind randomized multicenter 56 TACI Ig 56 polymerase inhibitor 56 investigational hepatitis C 56 PMA submission 56 Investigational Device Exemption 56 Premarket Approval PMA 56 Meets Primary Endpoint 56 ACCEDE 56 LIALDA 56 PNP inhibitor 56 CLL8 56 IMC #B 56 Triolex 56 ZEVALIN 56 Cetrorelix 56 cangrelor 56 Catena ® 56 Folotyn 56 velafermin belinostat 56 HGS ETR2 56 oral taxane 56 Brentuximab Vedotin SGN 56 iclaprim 56 unblinding 56 LEUKINE 56 Oncoscience AG 56 miconazole Lauriad 56 nab paclitaxel 56 DURATION 56 Biologic License Application 56 Fast Tracked Phase 56 castrate resistant prostate cancer 56 pediatric glioma 56 Rescula 56 rhC1INH 56 nimotuzumab 56 GATTEX ™ 56 ostarine 56 R roscovitine CDK cyclin 56 stated Michelle Berrey 56 Loramyc R 56 FORTIS M trial 56 topically applied SEPA 56 Ceflatonin 56 FORTIS M 56 refractory APL 56 registrational studies 56 Oglemilast 56 Evoltra TM 56 ACTEMRA 56 APTIVUS 56 Saforis 56 trastuzumab DM1 56 imetelstat GRN#L 56 Oxypurinol 56 refractory Hodgkin lymphoma 56 ROCKET AF 56 ApoB SNALP 56 metastatic renal cell 56 TORISEL 56 LUVENIQ 56 docetaxel chemotherapy 56 Fast Track designation 56 Trobalt 56 OZURDEX ® 56 ALKS 56 UVIDEM 56 Actemra tocilizumab 56 CIP TRAMADOL ER 56 Kynapid 56 Rezular 56 cariprazine 56 MoxDuo IR 56 Reolysin 56 Satraplatin 56 retigabine 56 post herpetic neuralgia PHN 56 AzaSite TM 56 injectable formulation 56 Lodotra TM 56 Zenvia 56 ASA# 55 ridaforolimus 55 Cimzia ® 55 M Vax 55 Virulizin 55 satraplatin Phase 55 Defibrotide 55 HuMax CD# 55 ADX# 55 Cleviprex TM clevidipine 55 tezampanel 55 arsenic trioxide injection 55 Cinryze TM 55 VELCADE 55 proprietary transdermal patch 55 LE SN# 55 prucalopride 55 Telatinib 55 Investigational 55 ongoing Phase IIIb 55 MIVI III 55 Phase III ThermoDox 55 unblinded 55 Cladribine Tablets 55 injectable enzyme 55 ruboxistaurin 55 Inhalation Solution 55 recurrent malignant glioma 55 OncoGel 55 Dose Ranging Study 55 azficel T 55 lucinactant 55 Clevudine 55 Ranexa 55 Dalbavancin 55 Stimuvax 55 IMPACT DCM 55 tezampanel NGX# 55 Xcellerated T Cells 55 Empatic 55 Tarsa Therapeutics 55 non metastatic osteosarcoma 55 Allovectin 7 R 55 registrational Phase 55 TASKi3 55 CUSTOM III 55 lubiprostone 55 ADVEXIN 55 JOULFERON 55 GSK# [002]

Back to home page